Browsing Modes for Business Users

Infliximab antibody | AbD19376_hIgG1

Human anti Infliximab

Product Type
Monoclonal Antibody

Product Code Applications Pack Size List Price Your Price Qty
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
E 0.1 mg loader
List Price Your Price

Human anti Infliximab, clone AbD19376_hIgG1, is an anti-idiotypic antibody that binds to both free infliximab and to infliximab bound to its target, TNFα. Clone AbD19376_hIgG1 does not inhibit the binding of infliximab to TNFα. It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Clone AbD19376_hIgG1 binds to an epitope outside the infliximab binding site. This epitope is shared with other chimeric antibodies that are highly homologous to infliximab including the chimeric antibody cetuximab but not rituximab.

Human anti Infliximab, clone AbD19376_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD19376_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays to measure total infliximab levels (free drug, partially bound and fully bound).

Infliximab (branded as Remicade®) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.

Infliximab is directed against Tumor Necrosis Factor Alpha (TNFα) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNFα expressing T-lymphocytes.

View a summary of all anti-infliximab antibodies.

Product Form
Human IgG1 antibody selected from the HuCAL phage display library and expressed in a human cell line.
Purified IgG prepared by affinity chromatography on Protein A.
Buffer Solution
Phosphate buffered saline.
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
The monovalent intrinsic affinity of this antibody was measured as KD=0.7 nM by real time, label-free molecular interaction analysis on immobilized inifliximab.
Approx. Protein Concentrations
Antibody concentration 0.5 mg/ml.
For research purposes only.
12 months from date of despatch.
This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See for details.
Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with HCA212 or HCA214 as the capture reagent.
Protocol: PK bridging ELISA to measure total drug
Protocol: ADA bridging ELISA

Description Product Code Applications Pack Size List Price Your Price Quantity
Hispec Assay Diluent BUF049A E IY 50 ml
List Price Your Price
Description Hispec Assay Diluent
Human anti Infliximab HCA212 E 0.1 mg
List Price Your Price
Description Human anti Infliximab
Human anti Infliximab HCA213 E 0.1 mg
List Price Your Price
Description Human anti Infliximab
Human anti Infliximab HCA214 E 0.1 mg
List Price Your Price
Description Human anti Infliximab
Human anti Infliximab HCA215 E 0.1 mg
List Price Your Price
Description Human anti Infliximab
LYNX Rapid HRP Antibody Conjugation Kit LNK002P CJ 3 Conjugations For 400µg Antibody
List Price Your Price
Description LYNX Rapid HRP Antibody Conjugation Kit
Mouse anti Human IgG (Fc) CH2 Domain:HRP MCA647P C * E 0.2 mg loader
List Price Your Price
Description Mouse anti Human IgG (Fc) CH2 Domain:HRP
Recombinant Human TNF Alpha PHP051 E FN WB 50 µg
List Price Your Price
Description Recombinant Human TNF Alpha

References for Infliximab antibody

  1. Kashiwagi, N. et al. (0) Method for measuring anti-drug antibody
    US Patent Application US2017315118A1

Licensed Use
For in vitro. research purposes and for commercial applications for the provision of in vitro. testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.


150458 159490 164655

If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.

View more products with INFLIXIMAB specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

Please note